Table 5.
Treatment characteristics of patients with VI due to DME.
| Patients with VI due to DME (N = 215) | ||
|---|---|---|
| Average time to treatment (days) (mean ± SD) | 27 ± 18 | |
| Lag to second treatment (days) (mean ± SD) | 59 ± 96 | |
|
| ||
| Type | Focal | Diffuse |
|
| ||
| Number of patients [n (%)] |
114 (53%) | 101 (47%) |
|
| ||
| Treatment type (% of all treatments recorded in patients' charts)* | ||
|
| ||
| Anti-VEGF monotherapy | 18.2% | 15.0% |
| Intravitreal Triamcinolone Acetonide (IVTA) | 1.0% | 3.0% |
| Other | 0.5% | 1.9% |
| Laser mono | 69.3% | 53.3% |
| Laser combo | ||
| Laser—anti-VEGF | 7.8% | 12.1% |
| Laser—IVTA | 3.1% | 15.0% |
*Some patients received more than one type of treatment; anti-VEGF: anti-vascular endothelial growth factor.